Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | Pembrolizumab |
| Indication/Tumor Type | esophageal carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | esophageal carcinoma | predicted - sensitive | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 30% (7/23, all partial responses), a median progression-free survival of 1.8 months, and a median overall survival of 7.0 months in patients with heavily pretreated, CD274 (PD-L1)-positive (1% or more) advanced esophageal carcinoma (PMID: 29116900; NCT02054806). | 29116900 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (29116900) | Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma. | Full reference... |